nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Temozolomide—melanoma	0.11	0.576	CbGbCtD
Lurasidone—CYP3A4—Vemurafenib—melanoma	0.0605	0.316	CbGbCtD
Lurasidone—CYP3A4—Docetaxel—melanoma	0.0207	0.108	CbGbCtD
Lurasidone—Deep vein thrombosis—Temozolomide—melanoma	0.0065	0.0155	CcSEcCtD
Lurasidone—Hypokinesia—Carmustine—melanoma	0.00606	0.0145	CcSEcCtD
Lurasidone—Extrapyramidal disorder—Temozolomide—melanoma	0.00525	0.0125	CcSEcCtD
Lurasidone—Eosinophilia—Vemurafenib—melanoma	0.00481	0.0115	CcSEcCtD
Lurasidone—Breast pain—Temozolomide—melanoma	0.00453	0.0108	CcSEcCtD
Lurasidone—Amenorrhoea—Temozolomide—melanoma	0.0045	0.0107	CcSEcCtD
Lurasidone—Infestation NOS—Vemurafenib—melanoma	0.00433	0.0103	CcSEcCtD
Lurasidone—Infestation—Vemurafenib—melanoma	0.00433	0.0103	CcSEcCtD
Lurasidone—Deep vein thrombosis—Docetaxel—melanoma	0.00432	0.0103	CcSEcCtD
Lurasidone—Gait disturbance—Carmustine—melanoma	0.00419	0.01	CcSEcCtD
Lurasidone—Neck pain—Carmustine—melanoma	0.00414	0.00989	CcSEcCtD
Lurasidone—Pulmonary embolism—Carmustine—melanoma	0.00409	0.00977	CcSEcCtD
Lurasidone—Gait disturbance—Temozolomide—melanoma	0.00405	0.00968	CcSEcCtD
Lurasidone—Pulmonary embolism—Temozolomide—melanoma	0.00395	0.00944	CcSEcCtD
Lurasidone—Connective tissue disorder—Vemurafenib—melanoma	0.00382	0.00912	CcSEcCtD
Lurasidone—Eye disorder—Vemurafenib—melanoma	0.00363	0.00867	CcSEcCtD
Lurasidone—Cardiac disorder—Vemurafenib—melanoma	0.00361	0.00861	CcSEcCtD
Lurasidone—Angiopathy—Vemurafenib—melanoma	0.00352	0.00842	CcSEcCtD
Lurasidone—Cerebrovascular accident—Bleomycin—melanoma	0.00347	0.00829	CcSEcCtD
Lurasidone—Diabetes mellitus—Carmustine—melanoma	0.00341	0.00816	CcSEcCtD
Lurasidone—Malnutrition—Vemurafenib—melanoma	0.00338	0.00808	CcSEcCtD
Lurasidone—Back pain—Vemurafenib—melanoma	0.00327	0.00781	CcSEcCtD
Lurasidone—Lethargy—Dactinomycin—melanoma	0.00324	0.00773	CcSEcCtD
Lurasidone—Hot flush—Temozolomide—melanoma	0.00307	0.00733	CcSEcCtD
Lurasidone—Menopausal symptoms—Temozolomide—melanoma	0.00304	0.00726	CcSEcCtD
Lurasidone—Amenorrhoea—Docetaxel—melanoma	0.00299	0.00715	CcSEcCtD
Lurasidone—Myalgia—Vemurafenib—melanoma	0.00288	0.00688	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00286	0.00683	CcSEcCtD
Lurasidone—Dysphagia—Dactinomycin—melanoma	0.00274	0.00655	CcSEcCtD
Lurasidone—Infection—Vemurafenib—melanoma	0.00274	0.00655	CcSEcCtD
Lurasidone—Nervous system disorder—Vemurafenib—melanoma	0.00271	0.00647	CcSEcCtD
Lurasidone—Skin disorder—Vemurafenib—melanoma	0.00268	0.0064	CcSEcCtD
Lurasidone—Pulmonary embolism—Docetaxel—melanoma	0.00263	0.00628	CcSEcCtD
Lurasidone—Blood pressure increased—Docetaxel—melanoma	0.00263	0.00628	CcSEcCtD
Lurasidone—Breast disorder—Temozolomide—melanoma	0.00259	0.00619	CcSEcCtD
Lurasidone—Hypotension—Vemurafenib—melanoma	0.00258	0.00616	CcSEcCtD
Lurasidone—Dysphagia—Carmustine—melanoma	0.00257	0.00613	CcSEcCtD
Lurasidone—Neutropenia—Dactinomycin—melanoma	0.00256	0.00613	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Temozolomide—melanoma	0.00253	0.00605	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00251	0.00601	CcSEcCtD
Lurasidone—Dysphagia—Temozolomide—melanoma	0.00248	0.00592	CcSEcCtD
Lurasidone—Neutropenia—Carmustine—melanoma	0.0024	0.00573	CcSEcCtD
Lurasidone—Decreased appetite—Vemurafenib—melanoma	0.0024	0.00573	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vemurafenib—melanoma	0.00238	0.00569	CcSEcCtD
Lurasidone—Fatigue—Vemurafenib—melanoma	0.00238	0.00568	CcSEcCtD
Lurasidone—Neutropenia—Temozolomide—melanoma	0.00232	0.00554	CcSEcCtD
Lurasidone—Dysuria—Temozolomide—melanoma	0.00232	0.00554	CcSEcCtD
Lurasidone—Hyperglycaemia—Carmustine—melanoma	0.00232	0.00553	CcSEcCtD
Lurasidone—Erectile dysfunction—Temozolomide—melanoma	0.00228	0.00546	CcSEcCtD
Lurasidone—Agranulocytosis—Dactinomycin—melanoma	0.00228	0.00545	CcSEcCtD
Lurasidone—Weight increased—Temozolomide—melanoma	0.00226	0.00539	CcSEcCtD
Lurasidone—Renal failure—Carmustine—melanoma	0.00225	0.00537	CcSEcCtD
Lurasidone—Hyperglycaemia—Temozolomide—melanoma	0.00224	0.00534	CcSEcCtD
Lurasidone—Urinary tract infection—Carmustine—melanoma	0.00222	0.00531	CcSEcCtD
Lurasidone—Infestation NOS—Temozolomide—melanoma	0.00221	0.00528	CcSEcCtD
Lurasidone—Infestation—Temozolomide—melanoma	0.00221	0.00528	CcSEcCtD
Lurasidone—Urinary tract infection—Temozolomide—melanoma	0.00215	0.00513	CcSEcCtD
Lurasidone—Hepatobiliary disease—Temozolomide—melanoma	0.00209	0.005	CcSEcCtD
Lurasidone—Hot flush—Docetaxel—melanoma	0.00204	0.00487	CcSEcCtD
Lurasidone—Menopausal symptoms—Docetaxel—melanoma	0.00202	0.00483	CcSEcCtD
Lurasidone—Connective tissue disorder—Carmustine—melanoma	0.00202	0.00482	CcSEcCtD
Lurasidone—Asthenia—Vemurafenib—melanoma	0.00198	0.00473	CcSEcCtD
Lurasidone—Urinary tract disorder—Temozolomide—melanoma	0.00196	0.00468	CcSEcCtD
Lurasidone—Pruritus—Vemurafenib—melanoma	0.00195	0.00466	CcSEcCtD
Lurasidone—Connective tissue disorder—Temozolomide—melanoma	0.00195	0.00466	CcSEcCtD
Lurasidone—Lethargy—Docetaxel—melanoma	0.00195	0.00465	CcSEcCtD
Lurasidone—Urethral disorder—Temozolomide—melanoma	0.00195	0.00465	CcSEcCtD
Lurasidone—Eye disorder—Carmustine—melanoma	0.00192	0.00459	CcSEcCtD
Lurasidone—Anaemia—Bleomycin—melanoma	0.00189	0.00452	CcSEcCtD
Lurasidone—Diarrhoea—Vemurafenib—melanoma	0.00189	0.00451	CcSEcCtD
Lurasidone—Eye disorder—Temozolomide—melanoma	0.00186	0.00443	CcSEcCtD
Lurasidone—Malaise—Bleomycin—melanoma	0.00185	0.00441	CcSEcCtD
Lurasidone—Cardiac disorder—Temozolomide—melanoma	0.00184	0.0044	CcSEcCtD
Lurasidone—Arrhythmia—Carmustine—melanoma	0.00184	0.00438	CcSEcCtD
Lurasidone—Leukopenia—Bleomycin—melanoma	0.00183	0.00438	CcSEcCtD
Lurasidone—Dizziness—Vemurafenib—melanoma	0.00183	0.00436	CcSEcCtD
Lurasidone—Angiopathy—Temozolomide—melanoma	0.0018	0.0043	CcSEcCtD
Lurasidone—Mental disorder—Carmustine—melanoma	0.0018	0.0043	CcSEcCtD
Lurasidone—Malnutrition—Carmustine—melanoma	0.00179	0.00427	CcSEcCtD
Lurasidone—Anaemia—Dactinomycin—melanoma	0.00177	0.00422	CcSEcCtD
Lurasidone—Vomiting—Vemurafenib—melanoma	0.00175	0.00419	CcSEcCtD
Lurasidone—Myalgia—Bleomycin—melanoma	0.00174	0.00417	CcSEcCtD
Lurasidone—Orthostatic hypotension—Docetaxel—melanoma	0.00174	0.00416	CcSEcCtD
Lurasidone—Abdominal pain upper—Docetaxel—melanoma	0.00174	0.00416	CcSEcCtD
Lurasidone—Rash—Vemurafenib—melanoma	0.00174	0.00416	CcSEcCtD
Lurasidone—Mental disorder—Temozolomide—melanoma	0.00174	0.00415	CcSEcCtD
Lurasidone—Dermatitis—Vemurafenib—melanoma	0.00174	0.00415	CcSEcCtD
Lurasidone—Back pain—Carmustine—melanoma	0.00173	0.00413	CcSEcCtD
Lurasidone—Malnutrition—Temozolomide—melanoma	0.00173	0.00413	CcSEcCtD
Lurasidone—Breast disorder—Docetaxel—melanoma	0.00172	0.00412	CcSEcCtD
Lurasidone—Malaise—Dactinomycin—melanoma	0.00172	0.00412	CcSEcCtD
Lurasidone—Leukopenia—Dactinomycin—melanoma	0.00171	0.00409	CcSEcCtD
Lurasidone—Nasopharyngitis—Docetaxel—melanoma	0.00171	0.00408	CcSEcCtD
Lurasidone—Vision blurred—Carmustine—melanoma	0.00169	0.00403	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Docetaxel—melanoma	0.00168	0.00402	CcSEcCtD
Lurasidone—Tremor—Carmustine—melanoma	0.00168	0.004	CcSEcCtD
Lurasidone—Back pain—Temozolomide—melanoma	0.00167	0.00399	CcSEcCtD
Lurasidone—Infection—Bleomycin—melanoma	0.00166	0.00397	CcSEcCtD
Lurasidone—Anaemia—Carmustine—melanoma	0.00165	0.00395	CcSEcCtD
Lurasidone—Dysphagia—Docetaxel—melanoma	0.00165	0.00394	CcSEcCtD
Lurasidone—Agitation—Carmustine—melanoma	0.00164	0.00393	CcSEcCtD
Lurasidone—Nausea—Vemurafenib—melanoma	0.00164	0.00392	CcSEcCtD
Lurasidone—Vision blurred—Temozolomide—melanoma	0.00163	0.00389	CcSEcCtD
Lurasidone—Myalgia—Dactinomycin—melanoma	0.00163	0.00389	CcSEcCtD
Lurasidone—Tremor—Temozolomide—melanoma	0.00162	0.00387	CcSEcCtD
Lurasidone—Angina pectoris—Docetaxel—melanoma	0.00161	0.00384	CcSEcCtD
Lurasidone—Leukopenia—Carmustine—melanoma	0.0016	0.00382	CcSEcCtD
Lurasidone—Anaemia—Temozolomide—melanoma	0.0016	0.00382	CcSEcCtD
Lurasidone—Agitation—Temozolomide—melanoma	0.00159	0.00379	CcSEcCtD
Lurasidone—Angioedema—Temozolomide—melanoma	0.00158	0.00377	CcSEcCtD
Lurasidone—Hypotension—Bleomycin—melanoma	0.00156	0.00373	CcSEcCtD
Lurasidone—Malaise—Temozolomide—melanoma	0.00156	0.00372	CcSEcCtD
Lurasidone—Vertigo—Temozolomide—melanoma	0.00155	0.00371	CcSEcCtD
Lurasidone—Convulsion—Carmustine—melanoma	0.00155	0.0037	CcSEcCtD
Lurasidone—Infection—Dactinomycin—melanoma	0.00155	0.0037	CcSEcCtD
Lurasidone—Leukopenia—Temozolomide—melanoma	0.00155	0.0037	CcSEcCtD
Lurasidone—Hypertension—Carmustine—melanoma	0.00154	0.00369	CcSEcCtD
Lurasidone—Neutropenia—Docetaxel—melanoma	0.00154	0.00368	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Bleomycin—melanoma	0.00152	0.00364	CcSEcCtD
Lurasidone—Myalgia—Carmustine—melanoma	0.00152	0.00364	CcSEcCtD
Lurasidone—Anxiety—Carmustine—melanoma	0.00152	0.00362	CcSEcCtD
Lurasidone—Weight increased—Docetaxel—melanoma	0.0015	0.00359	CcSEcCtD
Lurasidone—Convulsion—Temozolomide—melanoma	0.0015	0.00358	CcSEcCtD
Lurasidone—Hypertension—Temozolomide—melanoma	0.00149	0.00356	CcSEcCtD
Lurasidone—Dyspnoea—Bleomycin—melanoma	0.00149	0.00356	CcSEcCtD
Lurasidone—Myalgia—Temozolomide—melanoma	0.00147	0.00351	CcSEcCtD
Lurasidone—Infestation NOS—Docetaxel—melanoma	0.00147	0.00351	CcSEcCtD
Lurasidone—Infestation—Docetaxel—melanoma	0.00147	0.00351	CcSEcCtD
Lurasidone—Anxiety—Temozolomide—melanoma	0.00147	0.0035	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00146	0.00349	CcSEcCtD
Lurasidone—Decreased appetite—Bleomycin—melanoma	0.00145	0.00347	CcSEcCtD
Lurasidone—Infection—Carmustine—melanoma	0.00145	0.00346	CcSEcCtD
Lurasidone—Renal failure—Docetaxel—melanoma	0.00145	0.00345	CcSEcCtD
Lurasidone—Dry mouth—Temozolomide—melanoma	0.00144	0.00344	CcSEcCtD
Lurasidone—Tachycardia—Carmustine—melanoma	0.00142	0.0034	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00142	0.00339	CcSEcCtD
Lurasidone—Infection—Temozolomide—melanoma	0.0014	0.00335	CcSEcCtD
Lurasidone—Hepatobiliary disease—Docetaxel—melanoma	0.00139	0.00332	CcSEcCtD
Lurasidone—Nervous system disorder—Temozolomide—melanoma	0.00138	0.0033	CcSEcCtD
Lurasidone—Agranulocytosis—Docetaxel—melanoma	0.00137	0.00328	CcSEcCtD
Lurasidone—Skin disorder—Temozolomide—melanoma	0.00137	0.00327	CcSEcCtD
Lurasidone—Hypotension—Carmustine—melanoma	0.00136	0.00326	CcSEcCtD
Lurasidone—Hyperhidrosis—Temozolomide—melanoma	0.00136	0.00326	CcSEcCtD
Lurasidone—Decreased appetite—Dactinomycin—melanoma	0.00136	0.00324	CcSEcCtD
Lurasidone—Fatigue—Dactinomycin—melanoma	0.00134	0.00321	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Carmustine—melanoma	0.00133	0.00318	CcSEcCtD
Lurasidone—Insomnia—Carmustine—melanoma	0.00132	0.00315	CcSEcCtD
Lurasidone—Urinary tract disorder—Docetaxel—melanoma	0.0013	0.00311	CcSEcCtD
Lurasidone—Dyspnoea—Carmustine—melanoma	0.0013	0.00311	CcSEcCtD
Lurasidone—Somnolence—Carmustine—melanoma	0.0013	0.0031	CcSEcCtD
Lurasidone—Connective tissue disorder—Docetaxel—melanoma	0.0013	0.0031	CcSEcCtD
Lurasidone—Urethral disorder—Docetaxel—melanoma	0.00129	0.00309	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Temozolomide—melanoma	0.00129	0.00307	CcSEcCtD
Lurasidone—Insomnia—Temozolomide—melanoma	0.00128	0.00305	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dactinomycin—melanoma	0.00128	0.00305	CcSEcCtD
Lurasidone—Decreased appetite—Carmustine—melanoma	0.00127	0.00303	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Carmustine—melanoma	0.00126	0.00301	CcSEcCtD
Lurasidone—Dyspnoea—Temozolomide—melanoma	0.00126	0.003	CcSEcCtD
Lurasidone—Somnolence—Temozolomide—melanoma	0.00125	0.003	CcSEcCtD
Lurasidone—Dyspepsia—Temozolomide—melanoma	0.00124	0.00297	CcSEcCtD
Lurasidone—Eye disorder—Docetaxel—melanoma	0.00123	0.00295	CcSEcCtD
Lurasidone—Abdominal pain—Dactinomycin—melanoma	0.00123	0.00294	CcSEcCtD
Lurasidone—Decreased appetite—Temozolomide—melanoma	0.00123	0.00293	CcSEcCtD
Lurasidone—Cardiac disorder—Docetaxel—melanoma	0.00123	0.00293	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Temozolomide—melanoma	0.00122	0.00291	CcSEcCtD
Lurasidone—Fatigue—Temozolomide—melanoma	0.00122	0.0029	CcSEcCtD
Lurasidone—Asthenia—Bleomycin—melanoma	0.0012	0.00287	CcSEcCtD
Lurasidone—Angiopathy—Docetaxel—melanoma	0.0012	0.00286	CcSEcCtD
Lurasidone—Gastrointestinal pain—Carmustine—melanoma	0.00119	0.00285	CcSEcCtD
Lurasidone—Pruritus—Bleomycin—melanoma	0.00118	0.00283	CcSEcCtD
Lurasidone—Arrhythmia—Docetaxel—melanoma	0.00118	0.00282	CcSEcCtD
Lurasidone—Mental disorder—Docetaxel—melanoma	0.00116	0.00276	CcSEcCtD
Lurasidone—Abdominal pain—Carmustine—melanoma	0.00115	0.00276	CcSEcCtD
Lurasidone—Gastrointestinal pain—Temozolomide—melanoma	0.00115	0.00276	CcSEcCtD
Lurasidone—Malnutrition—Docetaxel—melanoma	0.00115	0.00275	CcSEcCtD
Lurasidone—Asthenia—Dactinomycin—melanoma	0.00112	0.00267	CcSEcCtD
Lurasidone—Abdominal pain—Temozolomide—melanoma	0.00112	0.00266	CcSEcCtD
Lurasidone—Back pain—Docetaxel—melanoma	0.00111	0.00266	CcSEcCtD
Lurasidone—Muscle spasms—Docetaxel—melanoma	0.0011	0.00264	CcSEcCtD
Lurasidone—Diarrhoea—Dactinomycin—melanoma	0.00107	0.00255	CcSEcCtD
Lurasidone—Vomiting—Bleomycin—melanoma	0.00106	0.00254	CcSEcCtD
Lurasidone—Anaemia—Docetaxel—melanoma	0.00106	0.00254	CcSEcCtD
Lurasidone—Rash—Bleomycin—melanoma	0.00105	0.00252	CcSEcCtD
Lurasidone—Dermatitis—Bleomycin—melanoma	0.00105	0.00252	CcSEcCtD
Lurasidone—Asthenia—Carmustine—melanoma	0.00105	0.0025	CcSEcCtD
Lurasidone—Syncope—Docetaxel—melanoma	0.00103	0.00246	CcSEcCtD
Lurasidone—Leukopenia—Docetaxel—melanoma	0.00103	0.00246	CcSEcCtD
Lurasidone—Asthenia—Temozolomide—melanoma	0.00101	0.00242	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—melanoma	0.00101	0.00241	CcSEcCtD
Lurasidone—Diarrhoea—Carmustine—melanoma	0.000999	0.00239	CcSEcCtD
Lurasidone—Pruritus—Temozolomide—melanoma	0.000998	0.00238	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—melanoma	0.000996	0.00238	CcSEcCtD
Lurasidone—Nausea—Bleomycin—melanoma	0.000993	0.00237	CcSEcCtD
Lurasidone—Hypertension—Docetaxel—melanoma	0.000992	0.00237	CcSEcCtD
Lurasidone—Vomiting—Dactinomycin—melanoma	0.000992	0.00237	CcSEcCtD
Lurasidone—Rash—Dactinomycin—melanoma	0.000983	0.00235	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—melanoma	0.000978	0.00234	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000972	0.00232	CcSEcCtD
Lurasidone—Dizziness—Carmustine—melanoma	0.000965	0.00231	CcSEcCtD
Lurasidone—Diarrhoea—Temozolomide—melanoma	0.000965	0.00231	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—melanoma	0.000957	0.00229	CcSEcCtD
Lurasidone—Dizziness—Temozolomide—melanoma	0.000933	0.00223	CcSEcCtD
Lurasidone—Infection—Docetaxel—melanoma	0.000932	0.00223	CcSEcCtD
Lurasidone—Vomiting—Carmustine—melanoma	0.000928	0.00222	CcSEcCtD
Lurasidone—Nausea—Dactinomycin—melanoma	0.000926	0.00221	CcSEcCtD
Lurasidone—Shock—Docetaxel—melanoma	0.000923	0.0022	CcSEcCtD
Lurasidone—Rash—Carmustine—melanoma	0.00092	0.0022	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—melanoma	0.00092	0.0022	CcSEcCtD
Lurasidone—Dermatitis—Carmustine—melanoma	0.000919	0.0022	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—melanoma	0.000915	0.00219	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—melanoma	0.000911	0.00218	CcSEcCtD
Lurasidone—Vomiting—Temozolomide—melanoma	0.000897	0.00214	CcSEcCtD
Lurasidone—Rash—Temozolomide—melanoma	0.000889	0.00212	CcSEcCtD
Lurasidone—Dermatitis—Temozolomide—melanoma	0.000889	0.00212	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—melanoma	0.000877	0.00209	CcSEcCtD
Lurasidone—Nausea—Carmustine—melanoma	0.000867	0.00207	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000855	0.00204	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—melanoma	0.000848	0.00203	CcSEcCtD
Lurasidone—Nausea—Temozolomide—melanoma	0.000838	0.002	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—melanoma	0.000836	0.002	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—melanoma	0.000834	0.00199	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—melanoma	0.000826	0.00197	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—melanoma	0.000815	0.00195	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—melanoma	0.00081	0.00193	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—melanoma	0.000809	0.00193	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—melanoma	0.000767	0.00183	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—melanoma	0.000742	0.00177	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—melanoma	0.000673	0.00161	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—melanoma	0.000664	0.00159	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—melanoma	0.000642	0.00153	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—melanoma	0.00062	0.00148	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—melanoma	0.000596	0.00142	CcSEcCtD
Lurasidone—Rash—Docetaxel—melanoma	0.000591	0.00141	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—melanoma	0.000591	0.00141	CcSEcCtD
Lurasidone—Nausea—Docetaxel—melanoma	0.000557	0.00133	CcSEcCtD
Lurasidone—DRD2—Signaling Pathways—EGF—melanoma	3.65e-05	9.36e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD80—melanoma	3.64e-05	9.34e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CG—melanoma	3.63e-05	9.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APC—melanoma	3.63e-05	9.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KIT—melanoma	3.63e-05	9.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—NRAS—melanoma	3.63e-05	9.32e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—melanoma	3.62e-05	9.28e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAP2K1—melanoma	3.6e-05	9.24e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGF—melanoma	3.59e-05	9.21e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KDR—melanoma	3.59e-05	9.2e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CD—melanoma	3.58e-05	9.18e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—melanoma	3.54e-05	9.09e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—FGF2—melanoma	3.54e-05	9.08e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK3—melanoma	3.54e-05	9.07e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—melanoma	3.5e-05	8.98e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK3—melanoma	3.48e-05	8.92e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—melanoma	3.47e-05	8.91e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—melanoma	3.47e-05	8.9e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FN1—melanoma	3.45e-05	8.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—melanoma	3.43e-05	8.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FGF2—melanoma	3.42e-05	8.79e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—melanoma	3.41e-05	8.76e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—melanoma	3.39e-05	8.71e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IGF1—melanoma	3.38e-05	8.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH1—melanoma	3.38e-05	8.67e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP17A1—melanoma	3.37e-05	8.65e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK1—melanoma	3.36e-05	8.63e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—melanoma	3.36e-05	8.63e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—melanoma	3.36e-05	8.62e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—melanoma	3.35e-05	8.6e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IGF1—melanoma	3.33e-05	8.53e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—melanoma	3.32e-05	8.53e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MDM2—melanoma	3.31e-05	8.5e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD80—melanoma	3.31e-05	8.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK1—melanoma	3.31e-05	8.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—melanoma	3.31e-05	8.49e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—melanoma	3.3e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KIT—melanoma	3.3e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—melanoma	3.3e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—melanoma	3.3e-05	8.48e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAP2K1—melanoma	3.27e-05	8.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—melanoma	3.27e-05	8.38e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—melanoma	3.26e-05	8.38e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—melanoma	3.24e-05	8.33e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—melanoma	3.22e-05	8.27e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—melanoma	3.22e-05	8.27e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	3.22e-05	8.25e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—melanoma	3.21e-05	8.25e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAP2K1—melanoma	3.21e-05	8.25e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—melanoma	3.21e-05	8.24e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—melanoma	3.2e-05	8.22e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—melanoma	3.19e-05	8.19e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNA11—melanoma	3.18e-05	8.16e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—melanoma	3.18e-05	8.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—melanoma	3.16e-05	8.12e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	3.16e-05	8.11e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—melanoma	3.16e-05	8.1e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—melanoma	3.13e-05	8.02e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—melanoma	3.12e-05	8.01e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—melanoma	3.12e-05	8e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—FASN—melanoma	3.11e-05	7.99e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGF2—melanoma	3.11e-05	7.97e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—melanoma	3.11e-05	7.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—melanoma	3.1e-05	7.94e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—melanoma	3.08e-05	7.89e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC5A5—melanoma	3.06e-05	7.86e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGF2—melanoma	3.06e-05	7.84e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK1—melanoma	3.05e-05	7.84e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—melanoma	3.05e-05	7.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—melanoma	3.03e-05	7.77e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF1—melanoma	3.03e-05	7.76e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—melanoma	3.02e-05	7.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK1—melanoma	3.01e-05	7.73e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—melanoma	3.01e-05	7.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—melanoma	3e-05	7.7e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—melanoma	3e-05	7.69e-05	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—melanoma	2.99e-05	7.67e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—melanoma	2.98e-05	7.64e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—melanoma	2.96e-05	7.6e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—melanoma	2.96e-05	7.59e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNAQ—melanoma	2.96e-05	7.59e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CD44—melanoma	2.96e-05	7.59e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—melanoma	2.94e-05	7.55e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—melanoma	2.93e-05	7.51e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAP2K1—melanoma	2.92e-05	7.5e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—melanoma	2.92e-05	7.49e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—melanoma	2.91e-05	7.46e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—melanoma	2.9e-05	7.45e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—melanoma	2.89e-05	7.42e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—melanoma	2.88e-05	7.4e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—melanoma	2.88e-05	7.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	2.88e-05	7.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—melanoma	2.87e-05	7.37e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—melanoma	2.87e-05	7.36e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—melanoma	2.87e-05	7.35e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—melanoma	2.86e-05	7.35e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—melanoma	2.86e-05	7.34e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNB1—melanoma	2.86e-05	7.33e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—melanoma	2.85e-05	7.31e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—melanoma	2.84e-05	7.3e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1B1—melanoma	2.84e-05	7.28e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—melanoma	2.83e-05	7.26e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—melanoma	2.82e-05	7.24e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—melanoma	2.8e-05	7.18e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—melanoma	2.79e-05	7.16e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—melanoma	2.79e-05	7.16e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—melanoma	2.78e-05	7.14e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—melanoma	2.78e-05	7.14e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGF2—melanoma	2.78e-05	7.14e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NFKB1—melanoma	2.77e-05	7.11e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNB1—melanoma	2.76e-05	7.09e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—melanoma	2.72e-05	6.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—melanoma	2.72e-05	6.97e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—melanoma	2.71e-05	6.95e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—melanoma	2.7e-05	6.93e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—melanoma	2.7e-05	6.93e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—melanoma	2.69e-05	6.91e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NFKB1—melanoma	2.68e-05	6.88e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—melanoma	2.67e-05	6.86e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—melanoma	2.66e-05	6.82e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—melanoma	2.65e-05	6.81e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—melanoma	2.65e-05	6.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—melanoma	2.63e-05	6.74e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—melanoma	2.63e-05	6.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—melanoma	2.62e-05	6.71e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	2.61e-05	6.7e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—melanoma	2.61e-05	6.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—melanoma	2.6e-05	6.68e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—melanoma	2.6e-05	6.67e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—melanoma	2.6e-05	6.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—melanoma	2.58e-05	6.63e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—melanoma	2.58e-05	6.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—melanoma	2.57e-05	6.58e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—melanoma	2.56e-05	6.58e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—melanoma	2.56e-05	6.57e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—melanoma	2.56e-05	6.56e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—melanoma	2.54e-05	6.52e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—melanoma	2.53e-05	6.5e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—melanoma	2.53e-05	6.5e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—melanoma	2.51e-05	6.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNB1—melanoma	2.51e-05	6.43e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—melanoma	2.49e-05	6.39e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—melanoma	2.49e-05	6.39e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—melanoma	2.48e-05	6.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNB1—melanoma	2.47e-05	6.33e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—melanoma	2.46e-05	6.31e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—melanoma	2.45e-05	6.29e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—melanoma	2.45e-05	6.29e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—melanoma	2.44e-05	6.27e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—melanoma	2.43e-05	6.24e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—melanoma	2.43e-05	6.24e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NFKB1—melanoma	2.43e-05	6.24e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—melanoma	2.42e-05	6.21e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—melanoma	2.42e-05	6.2e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—melanoma	2.41e-05	6.18e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—melanoma	2.41e-05	6.18e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—melanoma	2.4e-05	6.17e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—melanoma	2.4e-05	6.17e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NFKB1—melanoma	2.39e-05	6.14e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—melanoma	2.38e-05	6.12e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—melanoma	2.38e-05	6.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	2.38e-05	6.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	2.35e-05	6.03e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—melanoma	2.35e-05	6.02e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—melanoma	2.35e-05	6.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—melanoma	2.34e-05	5.99e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—melanoma	2.33e-05	5.98e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—melanoma	2.33e-05	5.97e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—melanoma	2.31e-05	5.94e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—melanoma	2.31e-05	5.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—melanoma	2.3e-05	5.91e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—melanoma	2.27e-05	5.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—melanoma	2.27e-05	5.82e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK1—melanoma	2.26e-05	5.81e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—melanoma	2.26e-05	5.81e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	2.24e-05	5.76e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—melanoma	2.24e-05	5.74e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—melanoma	2.21e-05	5.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—melanoma	2.2e-05	5.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	2.19e-05	5.63e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK1—melanoma	2.19e-05	5.62e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—melanoma	2.19e-05	5.62e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—melanoma	2.19e-05	5.61e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—melanoma	2.19e-05	5.61e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—melanoma	2.18e-05	5.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NFKB1—melanoma	2.18e-05	5.59e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—melanoma	2.17e-05	5.57e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—melanoma	2.16e-05	5.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—melanoma	2.15e-05	5.52e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PRKCA—melanoma	2.15e-05	5.51e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—melanoma	2.15e-05	5.5e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—melanoma	2.14e-05	5.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—melanoma	2.13e-05	5.48e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ERCC2—melanoma	2.13e-05	5.47e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—melanoma	2.09e-05	5.36e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—melanoma	2.07e-05	5.31e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—melanoma	2.05e-05	5.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—melanoma	2.03e-05	5.21e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—melanoma	2e-05	5.13e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK1—melanoma	1.99e-05	5.1e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—melanoma	1.99e-05	5.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—melanoma	1.98e-05	5.07e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—melanoma	1.96e-05	5.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—melanoma	1.96e-05	5.02e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK1—melanoma	1.96e-05	5.02e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—melanoma	1.95e-05	5.02e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—melanoma	1.95e-05	5.01e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—melanoma	1.9e-05	4.88e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—melanoma	1.9e-05	4.87e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—melanoma	1.88e-05	4.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—melanoma	1.87e-05	4.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—melanoma	1.86e-05	4.76e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—melanoma	1.85e-05	4.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—melanoma	1.85e-05	4.74e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—melanoma	1.84e-05	4.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—melanoma	1.82e-05	4.67e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—melanoma	1.82e-05	4.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK1—melanoma	1.78e-05	4.56e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—melanoma	1.78e-05	4.56e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—melanoma	1.76e-05	4.51e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—melanoma	1.74e-05	4.46e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—melanoma	1.72e-05	4.42e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—melanoma	1.7e-05	4.35e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—melanoma	1.68e-05	4.32e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—melanoma	1.68e-05	4.32e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—melanoma	1.68e-05	4.31e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—melanoma	1.67e-05	4.28e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—melanoma	1.64e-05	4.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—melanoma	1.62e-05	4.17e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—melanoma	1.6e-05	4.12e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—melanoma	1.6e-05	4.09e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—melanoma	1.57e-05	4.03e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—melanoma	1.55e-05	3.98e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	1.54e-05	3.96e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—melanoma	1.53e-05	3.92e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—melanoma	1.51e-05	3.87e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—melanoma	1.5e-05	3.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—melanoma	1.49e-05	3.83e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—melanoma	1.48e-05	3.8e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—melanoma	1.46e-05	3.75e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—melanoma	1.43e-05	3.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—melanoma	1.41e-05	3.61e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—melanoma	1.39e-05	3.56e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—melanoma	1.37e-05	3.51e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—melanoma	1.29e-05	3.31e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—melanoma	1.28e-05	3.28e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—melanoma	1.26e-05	3.24e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—melanoma	1.11e-05	2.86e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—melanoma	7.86e-06	2.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—melanoma	6.42e-06	1.65e-05	CbGpPWpGaD
